Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2017

Open Access 01-12-2017 | Review

Reduced cardiac function and risk of venous thromboembolism in Asian countries

Authors: Ruiqi Zhu, Yu Hu, Liang Tang

Published in: Thrombosis Journal | Issue 1/2017

Login to get access

Abstract

Patients with reduced cardiac function are thought to have a higher risk of venous thromboembolism (VTE). Additionally, they are vulnerable to complications of pulmonary embolism (PE) as well as right heart failure (HF), which in return is supposed to increase the rate of mortality. Studies focusing on VTE in heart failure patients were rare in Asian countries before the 21st century. Nowadays, more and more data are becoming available in this field in Asia. It is already known that heart failure can increase the risk of VTE, but so far a consensus on this issue has not been reached for many years, not only in Asian countries but all over the world. This condition may be due to the detailed pathological advancement in Virchow’s triad and some other theories. In clinical practice, VTE, especially PE is difficult to diagnose in patients with heart failure because of overlapping symptoms (e.g. cough and chest pain) and the elevation of laboratory markers (e.g. probrain natriuretic peptide (NT-proBNP) and D-dimer in both heart failure and VTE patients). Management of VTE in heart failure patients is also controversial because heart failure patients always have complications, such as renal failure and hepatic failure, which increase the risk of bleeding. In this study, we analyzed data from China, Japan, Korea, Singapore and India mainly to get a better understanding of the research progress in VTE in patients with heart failure. The aim of this review is to discuss the risk, incidence, advancement of diagnosis, management and prevention of VTE in patients with heart failure in Asian countries.
Literature
1.
Hwang WS. The rarity of pulmonary thromboembolism in asians. Singapore Med J. 1968;9(4):276–9.PubMed
2.
Kishimoto M, et al. Prevalence of venous thromboembolism at a teaching hospital in Okinawa, Japan. Thromb Haemost. 2005;93(5):876–9.PubMed
3.
Stein PD, et al. Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med. 2004;116(7):435–42.CrossRefPubMed
4.
White RH, et al. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005;93(2):298–305.PubMed
5.
Liew NC, et al. Asian venous thromboembolism guidelines: prevention of venous thromboembolism. Int Angiol. 2012;31(6):501–16.PubMed
6.
Leizorovicz A, et al. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. J Thromb Haemost. 2005;3(1):28–34.CrossRefPubMed
7.
Tang L, et al. Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol. 2016;3(1):e30–44.CrossRefPubMed
8.
Piazza G, Seddighzadeh A, Goldhaber SZ. Heart failure in patients with deep vein thrombosis. Am J Cardiol. 2008;101(7):1056–9.CrossRefPubMed
9.
10.
Monreal M, et al. Pulmonary embolism in patients with chronic obstructive pulmonary disease or congestive heart failure. Am J Med. 2006;119(10):851–8.CrossRefPubMed
11.
Darze ES, et al. Acute pulmonary embolism is an independent predictor of adverse events in severe decompensated heart failure patients. Chest. 2007;131(6):1838–43.CrossRefPubMed
12.
Alikhan R, Spyropoulos AC. Epidemiology of venous thromboembolism in cardiorespiratory and infectious disease. Am J Med. 2008;121(11):935–42.CrossRefPubMed
13.
Goldhaber SZ, et al. Risk factors for pulmonary embolism. The Framingham study. Am J Med. 1983;74(6):1023–8.CrossRefPubMed
14.
Greenstein J. Thrombosis and pulmonary embolism. S Afr Med J. 1945;19:377–80.PubMed
15.
Ota S, et al. Incidence and clinical predictors of deep vein thrombosis in patients hospitalized with heart failure in Japan. Circ J. 2009;73(8):1513–7.CrossRefPubMed
16.
Aniwan S, Rojnuckarin P. High incidence of symptomatic venous thromboembolism in Thai hospitalized medical patients without thromboprophylaxis. Blood Coagul Fibrinolysis. 2010;21(4):334–8.CrossRefPubMed
17.
Heit JA, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study. Arch Intern Med. 2000;160(6):809–15.CrossRefPubMed
18.
Sorensen HT, et al. Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation. 2011;124(13):1435–41.CrossRefPubMed
19.
Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case–control study. J Clin Epidemiol. 2001;54(8):810–6.CrossRefPubMed
20.
Ocak G, et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost. 2013;11(1):116–23.CrossRefPubMed
21.
Sellier E, et al. Risk factors for deep vein thrombosis in older patients: a multicenter study with systematic compression ultrasonography in postacute care facilities in France. J Am Geriatr Soc. 2008;56(2):224–30.CrossRefPubMed
22.
Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004;2(12):2156–61.CrossRefPubMed
23.
Matsuo H, et al. Frequency of deep vein thrombosis among hospitalized non-surgical Japanese patients with congestive heart failure. J Cardiol. 2014;64(6):430–4.CrossRefPubMed
24.
Lee CH, et al. Universal pharmacological thromboprophylaxis for total knee arthroplasty may not be necessary in low-risk populations: a nationwide study in Taiwan. J Thromb Haemost. 2012;10(1):56–63.CrossRefPubMed
25.
Pinjala R. Venous thromboembolism risk & prophylaxis in the acute hospital care setting (ENDORSE), a multinational cross-sectional study: results from the Indian subset data. Indian J Med Res. 2012;136(1):60–7.PubMedPubMedCentral
26.
Mebazaa A, et al. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation. 2014;130(5):410–8.CrossRefPubMed
27.
Wang Y, et al. Association of elevated NTproBNP with recurrent thromboembolic events after acute pulmonary embolism. Thromb Res. 2012;129(6):688–92.CrossRefPubMed
28.
Kociol RD, et al. B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: insights from the Acute Decompensated Heart Failure National Registry. Am Heart J. 2012;163(6):994–1001.CrossRefPubMed
29.
30.
31.
Shantsila E, Lip GY. The risk of thromboembolism in heart failure: does it merit anticoagulation therapy? Am J Cardiol. 2011;107(4):558–60.CrossRefPubMed
32.
O’Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol. 1999;83(9):1345–9.CrossRefPubMed
33.
Yamamoto K, et al. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol. 1995;25(7):1634–40.CrossRefPubMed
34.
Kapur NK, et al. Hemodynamic modulation of endocardial thromboresistance. Circulation. 2007;115(1):67–75.CrossRefPubMed
35.
Loubele ST, et al. Activated protein C protects against myocardial ischemia/reperfusion injury via inhibition of apoptosis and inflammation. Arterioscler Thromb Vasc Biol. 2009;29(7):1087–92.CrossRefPubMed
36.
Zannad F, et al. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. Int J Cardiol. 2013;167(5):1772–82.CrossRefPubMed
37.
38.
van der Poll T, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 1990;322(23):1622–7.CrossRefPubMed
39.
Chin BS, et al. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis. 2003;14(6):515–21.CrossRefPubMed
40.
Piazza G, Seddighzadeh A, Goldhaber SZ. Deep-vein thrombosis in the elderly. Clin Appl Thromb Hemost. 2008;14(4):393–8.CrossRefPubMed
41.
Konstantinides SV. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(45):3145–6.CrossRefPubMed
42.
Jia WB, Zhang CX, Xu ZM. [Pulmonary embolism misdiagnosis in China: a literature review (2001 to 2004)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2006;34(3):277–80.PubMed
43.
44.
JCS Joint Working Group. et al. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011;75(5):1258–81.
45.
Yorozu T. Prevention of venous thromboembolism and anticoagulant therapy. Masui. 2014;63(3):278–86.PubMed
46.
Cohen A, et al. Treating pulmonary embolism in Pacific Asia with direct oral anticoagulants. Thromb Res. 2015;136(2):196–207.CrossRefPubMed
47.
Buller HR, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–15.CrossRefPubMed
48.
Nakamura M, et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. J Thromb Haemost. 2015;13(9):1606–14.CrossRefPubMed
49.
Shen AY, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309–15.CrossRefPubMed
50.
Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost. 2014;111(5):789–97.CrossRefPubMed
51.
Kakkos SK, et al. The efficacy of a new portable sequential compression device (SCD Express) in preventing venous stasis. J Vasc Surg. 2005;42(2):296–303.CrossRefPubMed
52.
Urbankova J, et al. Intermittent pneumatic compression and deep vein thrombosis prevention. A meta-analysis in postoperative patients. Thromb Haemost. 2005;94(6):1181–5.PubMed
53.
Geerts WH, et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):381s–453s.CrossRefPubMed
54.
Ramakrishnan N. Thrombolysis is not warranted in submassive pulmonary embolism: a systematic review and meta-analysis. Crit Care Resusc. 2007;9(4):357–63.PubMed
55.
Lee J, et al. Prevention of venous thromboembolism in medical intensive care unit: a multicenter observational study in Korea. J Korean Med Sci. 2014;29(11):1572–6.CrossRefPubMedPubMedCentral
56.
Cohen AT, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–94.CrossRefPubMed
57.
Goldhaber SZ, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167–77.CrossRefPubMed
58.
Samama MM, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793–800.CrossRefPubMed
59.
Hull RD, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153(1):8–18.CrossRefPubMed
60.
Bang SM, Jang MJ. Prevention of venous thromboembolism, 2nd edition: Korean Society of Thrombosis and Hemostasis Evidence-based Clinical Practice Guidelines. J Korean Med Sci. 2014;29(2):164–71.
Metadata
Title
Reduced cardiac function and risk of venous thromboembolism in Asian countries
Authors
Ruiqi Zhu
Yu Hu
Liang Tang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2017
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-017-0135-3

Other articles of this Issue 1/2017

Thrombosis Journal 1/2017 Go to the issue

Review

Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy

Research

Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population

Review

The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV)

Research

The CD31 molecule: a possible neuroprotective agent in acute ischemic stroke?

Research

vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease

Research

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits